Table 2.

Characteristics of patients with a response to nivolumab plus ipilimumab* † ‡

Patient	Age, years	Sex	KPS score	No. of prior therapies§	Most recent prior IO therapy¶	Most recent prior therapy¶	BOR on most recent prior IO	Time on NIVO+IPI, months	Time to subsequent therapy, months** ††
1	Mid-70s	M	80	3	NIVO monotherapy	NIVO monotherapy	PD	23.1	25.5
2	Early 50s	M	90	2	NIVO monotherapy	NIVO monotherapy	SD	2.1	–
3	Early 80s	M	80	2	NIVO monotherapy	NIVO monotherapy	SD	5.3	–
4	Late 60s	M	80	8	NIVO+anti-LAG-3 antibody	NIVO+anti-LAG-3 antibody	SD	19.4	–
5	Late 70s	M	80	8	NIVO+anti-LAG-3 antibody	NIVO+anti-LAG-3 antibody	PD	6.2	4.6
6	Late 40s	F	70	1	NIVO+anti-LAG-3 antibody	NIVO+anti-LAG-3 antibody	PD	14.5	9.9
7	Early 70s	M	80	3	Avelumab/axitinib	TAK-228	PR	5.4	–
8	Early 50s	M	100	2	Atezolizumab/ bevacizumab	Cabozantinib	PR	23.8	–

*All patients had clear cell histology and all had metastatic disease at study entry.

†All patients had a nephrectomy.

‡All patients were Caucasian.

§The number of prior therapies includes patients who received prior IO therapy in a different FRACTION cohort.

¶The regimen setting for all prior regimens in all patients was metastatic disease.

**Dash indicates that at the time of the database lock, subsequent therapy was not initiated, documented, or was unable to be determined.

††Refers to subsequent therapy after progression or lack of response to nivolumab plus ipilimumab.

BOR, best overall response; IO, immuno-oncology; IPI, ipilimumab; KPS, Karnofsky performance status; LAG-3, lymphocyte-activation gene 3; NIVO, nivolumab; PD, progressive disease; PR, partial response; SD, stable disease.